Security Snapshot

Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM) Institutional Ownership

CUSIP: 45257U108

13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

197

Shares (Excl. Options)

116,653,135

Price

$21.87

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
-2,277,372
Value change
-$45,242,832
Number of holders
197
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
113,446,633
SEC-reported price per share
$22.54
Insider filing price
$22.54
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • IMNM - Immunome Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45257U108.
  • 197 institutions reported positions in Q1 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 183 to 197 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $2,540,755,654 to $2,543,864,825.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 197 institutions filings for Q1 2026.

Open SEC evidence

Security key

45257U108

Latest holder period

Q1 2026

13F holders

197

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
IMNM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
T. Rowe Price Investment Management, Inc. 14% +19% $353,135,357 +$123,423,292 16,364,011 +54% T. Rowe Price Investment Management, Inc. 31 Mar 2026
FMR LLC 15% +113% $152,894,064 +$80,670,694 13,056,709 +112% FMR LLC 30 Sep 2025
Sirenia Capital Management LP 6.1% $148,794,100 6,895,000 Sirenia Capital Management LP 31 Mar 2026
Redmile Group, LLC 4.9% -6% $119,960,738 -$3,442,010 5,558,885 -2.8% Redmile Group, LLC 31 Mar 2026
Immunome Aggregator, LP 6% $40,628,327 4,768,583 Immunome Aggregator, LP 31 Jan 2025
Enavate Sciences GP, LLC 4.3% $73,483,864 4,768,583 Enavate Sciences GP, LLC 18 Dec 2025
EcoR1 Capital, LLC 4.7% $34,756,616 4,079,415 EcoR1 Capital, LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 2.2% -55% $16,313,738 -$13,130,862 1,914,758 -45% JANUS HENDERSON GROUP PLC 31 Mar 2025

As of 31 Mar 2026, 197 institutional investors reported holding 116,653,135 shares of Immunome Inc. - Common Stock, par value $0.0001 per share (IMNM). This represents 103% of the company’s total 113,446,633 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
88%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 16,969,954 +2.5% 0.02% $371,132,894
T. Rowe Price Investment Management, Inc. 14% 16,364,011 +22% 0.25% $357,881,000
BlackRock, Inc. 7.2% 8,168,674 +7.6% 0% $178,648,901
Redmile Group, LLC 4.9% 5,558,885 -2.8% 8.1% $121,572,815
STATE STREET CORP 4.8% 5,399,901 +40% 0% $118,095,835
PRIMECAP MANAGEMENT CO/CA/ 4.2% 4,788,231 +2.2% 0.08% $104,718,612
WELLINGTON MANAGEMENT GROUP LLP 4.2% 4,731,977 +406% 0.02% $103,488,337
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 4,429,697 0% 0% $96,877,473
Driehaus Capital Management LLC 3.6% 4,099,901 +11% 0.66% $89,664,835
ENAVATE SCIENCES GP, LLC 3.2% 3,613,799 -24% 22% $79,033,784
PRICE T ROWE ASSOCIATES INC /MD/ 2.5% 2,858,863 -15% 0.01% $62,525,000
MORGAN STANLEY 2.5% 2,841,589 +66% 0% $62,145,575
JPMORGAN CHASE & CO 2.4% 2,777,836 -2.7% 0% $53,612,235
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,560,664 +8.4% 0% $56,012,726
SILVERARC CAPITAL MANAGEMENT, LLC 1.6% 1,850,278 +64% 4.8% $40,465,580
Sofinnova Investments, Inc. 1.5% 1,701,904 +5.2% 1.9% $37,220,640
Woodline Partners LP 1.4% 1,575,398 0% 0.13% $34,453,954
MARSHALL WACE, LLP 1.3% 1,480,788 +101% 0.03% $32,384,835
PRINCIPAL FINANCIAL GROUP INC 1.2% 1,376,867 -2% 0.02% $30,112,080
READYSTATE ASSET MANAGEMENT LP 1.1% 1,301,862 -29% 1.7% $28,471,722
Jefferies Financial Group Inc. 1% 1,160,715 -42% 0.31% $25,384,837
GOLDMAN SACHS GROUP INC 0.97% 1,101,476 +46% 0% $24,089,281
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 0.97% 1,097,836 +502% 0.03% $24,009,673
VANGUARD PORTFOLIO MANAGEMENT LLC 0.89% 1,006,975 0% 0% $22,022,543
NORTHERN TRUST CORP 0.79% 899,146 +8.5% 0% $19,664,322

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
22
Latest
Q1 2026
Rows shown
1-22 of 22
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 116,653,135 $2,543,864,825 -$45,242,832 $21.87 197
2025 Q4 118,328,952 $2,540,755,654 +$630,580,065 $21.48 183
2025 Q3 91,384,562 $1,070,118,014 +$140,281,752 $11.71 153
2025 Q2 79,431,966 $738,692,421 +$30,839,753 $9.30 142
2025 Q1 76,944,016 $518,447,649 +$156,654,047 $6.73 141
2024 Q4 53,313,664 $566,321,086 -$37,080,544 $10.62 119
2024 Q3 51,629,246 $754,701,793 +$58,776,153 $14.62 114
2024 Q2 47,779,242 $578,110,445 +$106,966,991 $12.10 112
2024 Q1 36,616,859 $903,617,775 +$377,900,927 $24.68 102
2023 Q4 21,490,560 $229,948,765 +$205,035,908 $10.70 57
2023 Q3 2,729,076 $22,706,803 +$3,521,335 $8.35 36
2023 Q2 1,949,082 $15,421,801 +$698,301 $7.91 35
2023 Q1 1,860,095 $9,343,739 -$1,198,225 $4.99 30
2022 Q4 2,100,648 $4,845,087 -$694,148 $2.21 28
2022 Q3 2,300,040 $10,208,297 -$14,594 $4.43 23
2022 Q2 2,313,613 $7,426,000 -$1,197,731 $3.21 24
2022 Q1 2,694,238 $15,433,000 -$858,955 $5.68 26
2021 Q4 2,790,928 $36,364,000 +$4,810,967 $12.96 28
2021 Q3 2,391,433 $58,321,000 +$6,054,335 $24.35 31
2021 Q2 2,376,109 $41,107,000 +$6,432,363 $17.30 25
2021 Q1 1,909,240 $64,673,000 +$1,324,022 $33.86 30
2020 Q4 2,013,500 $19,489,000 +$19,489,000 $9.68 24
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .